WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 4, 2018--
OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery,
development and commercialization of new treatment options for women and
families struggling with infertility, today announced that Christopher
Kroeger, M.D., Chief Executive Officer of OvaScience, will present a
corporate overview at the 36th Annual J.P. Morgan Healthcare
Conference on Thursday, January 11, 2018 at 11:00 a.m. PT (2:00 p.m. ET)
at the Westin St. Francis Hotel in San Francisco, California.
A live audio webcast of the presentation can be accessed by visiting the
investor section of the company’s website at www.ovascience.com.
A replay of the webcast will be archived on the OvaScience website for
30 days following the presentation.
OvaScience℠, Inc. (NASDAQ:OVAS) is a
company focused on the discovery, development and commercialization of
new treatment options for women and families struggling with
infertility. Each OvaScience treatment is based on the Company’s
proprietary technology platform that leverages the breakthrough
discovery of egg precursor (EggPC℠) cells – immature egg cells found
inside the protective ovarian lining. OvaScience is developing
OvaPrime℠, which could increase a woman’s egg reserve and OvaTure℠, a
potential in vitro fertilization (IVF) treatment that could help
a woman produce new, fertilizable eggs without hormone injections.
OvaScience’s AUGMENT℠ treatment, a fertility option designed to improve
IVF success rates, is available in certain IVF clinics in Canada and
Japan. OvaScience treatments are not available in the U.S. For more
information, visit www.ovascience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005233/en/
Jennifer Viera, 617-420-8748